<SEC-DOCUMENT>0001193125-23-146496.txt : 20230517
<SEC-HEADER>0001193125-23-146496.hdr.sgml : 20230517
<ACCEPTANCE-DATETIME>20230517060649
ACCESSION NUMBER:		0001193125-23-146496
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230517
FILED AS OF DATE:		20230517
DATE AS OF CHANGE:		20230517

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		23929575

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d603894d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated May&nbsp;17, 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 33, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><A HREF="d603894dex991.htm">Immutep&#146;s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line
 Non-Small Cell Lung Cancer </A></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: May&nbsp;17, 2023 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d603894dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g603894snap1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep&#146;s Efti in Combination with Pembrolizumab Achieves Excellent Initial </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Overall Survival Benefit in 1st Line <FONT STYLE="white-space:nowrap">Non-Small</FONT> Cell Lung Cancer </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Immuno-oncology combination of eftilagimod alpha (efti) and the leading <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy generates meaningful long-term survival in <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer patients in Phase II <FONT STYLE="white-space:nowrap">TACTI-002</FONT> trial
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Initial median Overall Survival of 25 months in <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung
cancer patients with <U>&gt;</U>1% <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression, a key area of focus for future development of efti </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Result is above reported rates of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> monotherapy and various immune checkpoint inhibitor combinations with and without chemotherapy </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Based on compelling initial results, the Data Monitoring Committee recommends extending overall survival <FONT
STYLE="white-space:nowrap">follow-up</FONT> collection to show mature <FONT STYLE="white-space:nowrap">3-year</FONT> and potentially <FONT STYLE="white-space:nowrap">5-year</FONT> rates </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">More mature Overall Survival data and additional efficacy and safety results to be presented at a major medical
conference in H2 CY2023 </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; 17</B><B></B><B>&nbsp;May </B><B>2023 &#150;</B> <U>Immutep Limited</U> (ASX: IMM;
NASDAQ: IMMP) (&#147;Immutep&#148; or &#147;the Company&#148;), a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and autoimmune disease, today announces that efti, a
soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> MHC Class&nbsp;II agonist, in combination with MSD&#146;s (Merck&nbsp;&amp; Co., Inc.,
Rahway, NJ, USA) <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) achieved robust initial Overall Survival (OS) in
1st line <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (1L NSCLC) patients in the Phase II <FONT STYLE="white-space:nowrap">TACTI-002</FONT> trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This immuno-oncology (IO) investigational combination, without the use of chemotherapy, led to excellent initial survival results in the overall <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">intent-to-treat</FONT></FONT> (ITT) 1L NSCLC patient population (N=114), regardless of <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression status. Importantly, an initial median OS of
25 months has been attained in those 1L NSCLC patients (N=58) who have a <FONT STYLE="white-space:nowrap">PD-L1</FONT> Tumor Proportion Score (TPS) of <U>&gt;</U>1%, a key area of focus for efti&#146;s future clinical development and for which Fast
Track designation was granted <U>in October 2022</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notably, the median <FONT STYLE="white-space:nowrap">25.0-month</FONT> OS compares favourably to
reported historical results for patients with the same <FONT STYLE="white-space:nowrap">PD-L1</FONT> TPS of <U>&gt;</U>1% from registration trials of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> monotherapy <FONT
STYLE="white-space:nowrap">(16.4-month</FONT> median OS); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">combinations of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> with
chemotherapy <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(15.8-to-23.3-month</FONT></FONT></FONT> median OS) or with <FONT STYLE="white-space:nowrap">anti-CTLA-4</FONT> <FONT
STYLE="white-space:nowrap">(17.1-month</FONT> median OS). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the exceptional survival data with a minimum <FONT
STYLE="white-space:nowrap">follow-up</FONT> of now 14 months, the Data Monitoring Committee recommends extending the OS <FONT STYLE="white-space:nowrap">follow-up</FONT> collection to show mature <FONT STYLE="white-space:nowrap">3-year</FONT> and
potentially <FONT STYLE="white-space:nowrap">5-year</FONT> survival rates of this novel <FONT STYLE="white-space:nowrap">IO-IO</FONT> combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Collectively, the breadth of efficacy and safety data emerging from the large number of 1L NSCLC patients in the Phase II
<FONT STYLE="white-space:nowrap">TACTI-002</FONT> trial offers compelling evidence of efti&#146;s substantial impact in safely stimulating the patients&#146; immune response to fight cancer. These initial OS results are supported by a strong interim
median Duration of Response of 21.6 months in the ITT population (N=114), including over <FONT STYLE="white-space:nowrap">one-third</FONT> of patients with negative <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression (N=32), and the high 48.3%
response rate achieved with efti in combination with pembrolizumab in 1L NSCLC patients with a <FONT STYLE="white-space:nowrap">PD-L1</FONT> TPS of <U>&gt;</U>1% (N=58), <U>as reported in a late-breaking oral abstract presentation</U> at the Society
for Immunotherapy of Cancer (SITC) Meeting in 2022. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g603894snap1.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr Martin Forster of the UCL Cancer Institute and University College London Hospital NHS Foundation, London,
UK, and <FONT STYLE="white-space:nowrap">TACTI-002</FONT> Investigator, said: &#147;These initial overall survival results from the <FONT STYLE="white-space:nowrap">TACTI-002</FONT> trial are clinically meaningful and build upon the strength of the
efficacy data emerging from this exciting novel investigational combination of efti with pembrolizumab. Importantly, the favourable safety profile of this immunotherapy regimen has continued, and to see these deep and durable responses without any
additional toxicity from what would be expected from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> monotherapy is very encouraging.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Efti&#146;s clinical results achieved to date in combination with pembrolizumab are increasingly robust and continue to justify the attention given to
this novel <FONT STYLE="white-space:nowrap">IO-IO</FONT> combination through invitations to make oral presentations at two prestigious conferences, ASCO and SITC, last year. We now are showing excellent initial overall survival, which is the gold
standard benchmark within oncology, across the entire <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">intent-to-treat</FONT></FONT> population of 1st line NSCLC patients in our Phase II trial. For
<FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer patients with <U>&gt;</U>1% <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression, a key focus for future development and for which efti in combination with pembrolizumab has Fast
Track status, the survival benefit is impressive. We look forward to presenting more mature data at a major medical conference later this year,&#148; said Marc Voigt, Immutep&#146;s CEO. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;This new data adds to the body of evidence that efti&#146;s novel activation of antigen-presenting cells provides a powerful boost to the immune system,
which furthers the potential of immune checkpoint inhibitors. Fundamentally, efti is leading to a significant systemic expansion of memory cytotoxic T cells that
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-(L)1</FONT></FONT> therapies can act upon. Indeed, the combination of efti plus <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> leads
to a superior median OS of <FONT STYLE="white-space:nowrap">25.0-months</FONT> as compared to <FONT STYLE="white-space:nowrap">17.1-months</FONT> for the registered <FONT STYLE="white-space:nowrap">IO-IO</FONT> combination of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> plus <FONT STYLE="white-space:nowrap">anti-CTLA-4,</FONT> with much less toxicity. Perhaps most importantly, as the only MHC Class&nbsp;II agonist in clinical
development today, efti is generating this profound immune response across a variety of solid tumour indications, even with low <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression, in a unique and safe manner,&#148; noted Fr&eacute;d&eacute;ric
Triebel, M.D., Ph.D, Immutep&#146;s CSO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lung cancer is the second most common cancer. <FONT STYLE="white-space:nowrap">Non-small</FONT> cell lung cancer
accounts for approximately <FONT STYLE="white-space:nowrap">80-85%</FONT> of all lung cancers, impacting an estimated 1.87&nbsp;million people annually, and is the highest cause of death among all cancers <SUP
STYLE="font-size:75%; vertical-align:top"><FONT STYLE="white-space:nowrap">1-3</FONT></SUP>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> is a registered trademark of Merck Sharp&nbsp;&amp; Dohme LLC, a subsidiary of
Merck&nbsp;&amp; Co., Inc., Rahway, NJ, USA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Eftilagimod Alpha (Efti) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is Immutep&#146;s proprietary soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein and MHC Class&nbsp;II agonist that stimulates both innate and
adaptive immunity for the treatment of cancer. As a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC) activator, efti binds to MHC (major histocompatibility complex)
Class&nbsp;II molecules on APC leading to activation and proliferation of CD8+ cytotoxic T cells, CD4+ helper T cells, dendritic cells, NK cells, and monocytes. It also upregulates the expression of key biological molecules like <FONT
STYLE="white-space:nowrap">IFN-</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> and CXCL10 that further boost the immune system&#146;s ability to fight cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is under evaluation for a variety of solid tumours including <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC), head and neck
squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its favourable safety profile enables various combinations, including with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-[L]1</FONT></FONT> immunotherapy
and/or chemotherapy. Efti has received Fast Track Designation in 1st line HNSCC and in 1st line NSCLC from the United States Food and Drug Administration (FDA). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g603894snap1.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the <FONT STYLE="white-space:nowrap">TACTI-002</FONT> Trial </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">TACTI-002</FONT> (Two ACTive Immunotherapies) is being conducted in collaboration with Merck&nbsp;&amp; Co., Inc., Rahway, NJ,
USA (known as &#147;MSD&#148; outside the United States and Canada). The study is evaluating the combination of eftilagimod alpha (efti) with MSD&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT>
therapy KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) in patients with second line head and neck squamous cell carcinoma or <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer in first and second
line. The trial is a Phase II, Simon&#146;s <FONT STYLE="white-space:nowrap">two-stage,</FONT> <FONT STYLE="white-space:nowrap">non-comparative,</FONT> open-label, <FONT STYLE="white-space:nowrap">single-arm,</FONT> multicentre clinical study that
is taking place in study centres across Australia, Europe, and the US. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patients participate in one of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Part A - first line <FONT STYLE="white-space:nowrap">Non-Small</FONT> Cell Lung Cancer (NSCLC), <FONT
STYLE="white-space:nowrap">PD-X</FONT> na&iuml;ve </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Part B - second line NSCLC, <FONT STYLE="white-space:nowrap">PD-X</FONT> refractory </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Part C - second line Head and Neck Squamous Cell Carcinoma (HNSCC), <FONT STYLE="white-space:nowrap">PD-X</FONT>
na&iuml;ve </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">TACTI-002</FONT> is an <FONT STYLE="white-space:nowrap">all-comer</FONT> study in terms of <FONT
STYLE="white-space:nowrap">PD-L1</FONT> status, a well-known predictive marker for response to pembrolizumab monotherapy especially in NSCLC and HNSCC. More information about the trial can be found on Immutep&#146;s website or on ClinicalTrials.gov
(Identifier: NCT03625323). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is
a clinical stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte
Activation <FONT STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to
leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit <U>www.immutep.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong,
Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268; <U>cstrong@citadelmagnus.com</U> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor Relations and
Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the Board of Immutep Limited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;- </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Global Cancer Observatory, <U>Lung Cancer Fact Sheet</U> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">American Cancer Society, <U>About Lung Cancer</U> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">3</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">CDC, <U>Lung Cancer Statistics</U> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>,
Level&nbsp;33, Australia Square, 264 George Street, Sydney NSW 2000, Australia </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g603894snap1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g603894snap1.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
MJW]['I]G)<RD[4'0=2>PI-V1,Y<BNSBIO$NMSWC1H1;!<DIY6=H]\@FL.>1P
M.O5;LC=TG6[K-I%J30EKI<Q,AP?HP[9K2,GU.FG4DK*?4Z$&M#H%H * "@"K
MJ-_#IFGS7EQGRHEW':,D_2@"#1=9MM=L!>6H<)N*E7&""* -&@ H * "@ H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
4!0 4 % !0 4 % !0 4 % !0!_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
